strive maintain scale evolv
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
develop pharmaceut platform
address comprehens sourc distribut need
manufactur provid employe
electron inventori platform compani equip ship
million product day world-wide global scale
sheer pharmaceut volum enabl compani
negoti competit price effici provid access
vast portfolio drug core busi roughli
revenu focus pharmaceut distribut
balanc revenu attribut acquir busi
handl roughli third drug sold
unit state creat extens footprint
physician-administ product key anchor custom
within commun compani oper effici
highli regul environ provid insul
core busi distribut servic larg driven drug
price drug mix gener versu brand drug overal
volum deceler pharmaceut drug growth due
slower brand drug inflat shift mix favor gener
drug lower price slower introduct blockbust drug
increas provid negoti leverag oper margin
pressur high cost specialti
pharmaceut drug off-set declin stem
introduct fewer brand drug overal oper
margin rel displac brand drug like lower
tout highest concentr among
competitor specialti drug repres roughli overal
revenu like help compani grow slightli faster
competitor recent similar two largest
distributor compani grown signific size
regular acquisit like necessari supplement growth
off-set overal market deceler slower growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
lead global third-parti logist provid
engag wholesal pharmaceut sourc distribut specialti
brand-nam gener pharmaceut relat servic
acute-car hospit health system independ chain retail
pharmaci mail order pharmaci medic clinic long-term care
altern site pharmaci physician practic dialysi clinic
healthcar custom acquir smaller compani manag
attain abil compound steril prepar distribut veterinari
pharmaceut vaccin transport biopharmaceut provid
inventori reimburs consult servic provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend fve across board apr
reassess pharmaceut distribut
segment light evolv competit regulatori
environ base continu declin pharmaceut
spend growth extern shock threat lower
moat rate
wide narrow neg moat
trend also reduc fair valu estim
despit stabl foothold oligopoli market
three compani handl market role
pharmaceut distributor continu evolv
increasingli competit highli regul environ
scale regulatori requir provid insul
maintain share gener market return
competit pressur continu build declin
reimburs healthcar consolid declin
pharmaceut revenu growth declin due slower
inflat shift revenu mix consist overal
pharmaceut spend trend expect revenu growth
pharmaceut distributor declin overal
growth pharmaceut spend declin
double-digit growth past three
four year oper margin industri
declin lower level like persist
signific declin pharmaceut market growth
caus distributor seek altern growth
channel acquisit entri new
area outsid core compet costli
extern shock elimin rebat
increas price transpar would diminish
pharmaceut distributor valu negoti
transpar price provid manufactur
would less like need middleman negoti rate
would give custom leverag renegoti
distribut contract deterior distributor
lower
per share
adjust assumpt continu reimburs
pressur increas consolid expect retail
pharmaci provid continu press better
negoti rate put pressur top-lin growth
increas specialti revenu like weigh
overal profit lastli anticip
make
acquisit seek altern growth channel
incorpor forecast new fair
valu estim impli fiscal ev/ebitda multipl
time free cash flow yield dividend yield
continu
revenu driver price volum mix
disclos made sever assumpt project
industri growth except potenti extern
market shock anticip market share shift
dramat near term result anticip
overal annual top-lin growth roughli larg
benefit growth specialti pipelin
increas number therapi age popul
brand drug
compon growth varieti factor includ
neg slower growth introduct
new drug lesser extent gener
deflat
lower spend hepat
prescript opioid factor net anticip
industri revenu growth roughli
similar industri rang accord iqvia
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financ
inventori manag servic
provid negoti provid specialti drug distribut
base current high level custom concentr
increas competit environ potenti
regulatori chang believ limit upsid
base scenario per share
bull-cas fair valu estim per share
growth overal revenu project
grow basi point higher base scenario
drive net growth slightli anticip industri
project scenario oper margin
anticip improv basi point due increas
revenu higher averag profit
bear-cas fair estim per share scenario
inflat increas volum slightli offset
price deflat lower growth anticip decreas
oper margin basi point signific
legisl regulatori chang extern shock
increas uncertainti downsid
uncertainti rate pharmaceut
distributor stand medium due competit
environ potenti extern shock includ
legisl chang increas price transpar
potenti entranc new competitor
attribut cost advantag
effect oper oligopoli
entrench within custom base
expect revenu growth continu slow
declin histor compani growth high
singl digit histor revenu growth continu
lumpi due mix drug introduct inflat
gener albeit less industri roughli
howev lower gener price point would translat
roughli half overal pharmaceut distribut revenu
last three four year oper margin
industri declin oper margin
declin
fiscal first quarter
model oper margin declin
fiscal next five year
part valuat framework addit
base-cas dcf also model bull bear case
valuat scenario critic debat
surround compani abil entrench exist
partnership manufactur
negoti provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
largest pharmaceut distributor global contract
manufactur capabl vertic integr
provid retail pharmaci chain canada
europ closest pure-play
pharmaceut distributor platform base insid
close provid retail pharmaci cardin
smallest three private-label
commod manufactur capabl medic devic
compani invest infrastructur provid
abil navig highli regul drug market scale
also enabl compani negoti behalf
provid retail pharmaci requir infrastructur
regulatori hurdl requir logist manag
insul new entrant
cardin health
repres market role pharmaceut
distributor evolv increas number new
therapi format govern regulatori organ
regulatori requir licensur manufactur
retail pharmaci pharmaceut distributor
evolut compani continu invest
physic infrastructur provid logist
support effici compani scale also provid
abil negoti lower price drug manufactur
across comprehens portfolio gener brand
specialti drug behalf provid acut hospit
clinic mail pharmaci retail pharmaci
financ function provid manufactur
support commerci manufactur invest
autom infrastructur escal past
decad invest nearli
billion capit expenditur billion
acquisit billion strengthen foothold
merger amerisourc health bergen brunswig
slightli differ geographi creat larger entiti
stronger nation presenc sinc initi merger
compani made dozen acquisit rang
contract packag courier servic temperature-control
item world courier group home infus igg america
lead anim pharmaceut vaccin distributor
mwi veterinari suppli addit sever smaller
focus pharmaceut
distribut acquisit provid increment
revenu channel limit growth potenti
special natur success
acquisit around specialti account
increas percentag overal volum due rapid
acceler new specialti drug
manufactur product
commod natur servic reflect low
oper margin despit low margin compani
enjoy return invest capit larg
due scale growth driven strong drug inflat
pharmaceut revenu declin slower
inflat shift revenu mix margin like
declin increas negoti leverag
custom rise healthcar consolid
amerisourc top custom repres
revenu oper margin declin exacerb
rise govern scrutini acquir busi
drug compound factor weigh roic
despit near-term improv trend like
persist
current lack price transpar signific
variat list invoic price day-to-day
price volatil regulatori complianc recal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
provid retail pharmaci
infrastructur quickli manag avail inform
negoti competit price manufactur
amerisourc volum also provid abil negoti
lower price drug manufactur increment scale
abil provid assist
inventori manag complianc financ
convers compani also support commerci
new drug deliveri product manufactur
like
custom top custom
repres revenu market pressur
leverag pharmaceut distributor
custom
largest contributor
deterior overal industri margin
declin consecut last three four year even
manufactur appear test altern
direct shipment matur drug may limit
could also neg factor
secur moat due scale
uncertain drug price environ grow
custom leverag limit narrow recent
howev pharmaceut revenu declin
slower inflat shift revenu mix increas
gener versu brand drug meanwhil margin
declin like due part increas negoti
leverag custom driven healthcar provid
consolid think oper margin pressur
like persist
trend rate despit insul provid
compani amass physic infrastructur
complex regulatori environ overal market
pressur continu build larg due declin
reimburs healthcar consolid declin
pressur manufactur provid press focu
contain cost result pharmaceut
distribut client activ solicit bid negoti
better price commod servic distributor
also includ client gener sourc joint ventur red
oak sourc cardin
walgreen claruson wal-mart
healthcar consolid also
increas concentr pharmaceut distribut
signific declin pharmaceut market
growth caus distributor seek altern
channel acquisit entri new
area outsid core compet prove costli
compound busi acquir pharmedium sinc
regulatori scrutini compound increas
compani close largest site earli
continu expand new area
remain relev off-set declin core busi
execut regulatori risk increas concern
addit extern shock highli contest
reduct rebat increas price transpar
would diminish pharmaceut distributor
valu negoti transpar price
provid manufactur would less like need middl
man negoti rate would give custom
leverag renegoti distribut contract
amazon may immedi threat next sever
year discount altogeth
signific resourc appear method
gather expertis compet healthcar distribut
amazon signific inventori manag expertis
quietli accumul core piec need
compet pharmaceut distributor includ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pillpack state distributor licens joint
ventur jpmorgan berkshir hathaway
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
key drug distributor handl
third pharmaceut distribut market
compani infrastructur provid scale abil
effect negoti price provid
inventori
oth compani servic enabl provid
manufactur focu core busi
outsourc logist drug highli
requir high sunk cost low oper margin
provid barrier entri highli matur
rivalri
declin reimburs matur market could
limit growth pressur profit
compani continu make acquisit
outsid core compet seek altern
channel growth execut regulatori risk
oextern shock legisl action increas
drug price transpar entranc
competitor could disrupt current oligopoli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ enjoy posit solid
financi strength aris strong balanc sheet
posit matur market fiscal
billion cash
equival off-set billion debt result net debt
billion debt/capit ratio fiscal gross
leverag time adjust ebitda million senior
note outstand due view
challeng compani free cash flow gener
billion fiscal
lead pharmaceut distributor amerisourcebergen
disciplin acquisit dividend strategi
compani regularli complet acquisit increas
cross-sel opportun exist custom fuel
growth manag spent roughli billion
averag acquisit last four fiscal year
acceler histor trend annual common
stock dividend averag million last
year acceler million fiscal
dividend yield two peer
repurchas nearli billion worth
stock fiscal fiscal million
buyback fiscal manag roughli
million remain share repurchas author
believ compani continu repurchas share
exist author beyond
oper matur oligopoli
loss larg custom high custom concentr
regulatori chang entri new competitor
signific resourc overal market dynam could
reduc abil negoti drug manufactur
custom continu pressur drug price pose
risk compani includ deflat gener drug
price increas gener mix slower growth
pharmaceut pipelin lower spend hepat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
 opioid risk could eman propos
govern rule seek increas transpar drug
price elimin rebat pbm propos
regulatori chang would reduc cost drug
current pass-through revenu basi
pharmaci wholesal compens although
pharmaci distributor would opportun
negoti drugmak provid
uncertainti abil negoti industri
rate paid current increas transpar
continu consolid retail pharmaci could affect
compani abil negoti lower price
cornerston servic although threat new
competitor immin amazon compani
signific inventori manag expertis
quietli accumul core piec need compet
pharmaceut distributor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
board director
stewardship rate overal leader season
divers background pharmaceut distribut
see govern issu
steven colli chairman presid chief execut
offic join compani specialti
pharmaci distribut segment signific
contributor key area growth compani
colli accumul year
experi pharmaci distribut
jame cleari jr execut vice presid chief
financi offic core member mwi veterinari
suppli compani acquir
sinc acquisit increas
respons execut vice presid group
presid global commerci servic
anim health segment current role cfo
robert mauch execut vice presid group presid
pharmaceut distribut strateg global sourc
join compani acquisit xcenda
founder year healthcar
experi sinc acquisit assist improv
custom experi compani oper chief
oper offic execut vice presid
presid
repres date owner name posit common share held report holder issuer
fidel manag research compani
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend fve across board apr
reassess pharmaceut distribut
segment light evolv competit regulatori
environ base continu declin pharmaceut
spend growth extern shock threat lower
moat rate
wide narrow neg moat
trend also reduc fair valu estim
despit stabl foothold oligopoli market
three compani handl market role
pharmaceut distributor continu evolv
increasingli competit highli regul environ
scale regulatori requir provid insul
maintain share gener market return
competit pressur continu build declin
reimburs healthcar consolid declin
pharmaceut revenu growth declin due slower
inflat shift revenu mix consist overal
pharmaceut spend trend expect revenu growth
pharmaceut distributor declin overal
growth pharmaceut spend declin
double-digit growth past three
four year oper margin industri
declin lower level like persist
signific declin pharmaceut market growth
caus distributor seek altern growth
channel acquisit entri new
area outsid core compet costli
extern shock elimin rebat
increas price transpar would diminish
pharmaceut distributor valu negoti
transpar price provid manufactur
would less like need middleman negoti rate
would give custom leverag renegoti
distribut contract deterior distributor
amerisourc post solid first quarter drug
result larg match expect ran ahead
consensu expect strength core drug
distribut busi partli offset pressur drug
compound arm overal expect major
chang fair valu estim moat rate base
result
price pressur weigh drug distribut
busi increas pharmaci leverag quarterli
result help support stabil compani
distribut divis post top-lin gain close
strength come larger custom specialti
drug continu believ growth specialti drug
driver overal market quarterli
strength segment amerisourc bode well
compani howev pharmedium drug compound
challeng persist memphi facil like
reopen fiscal remind fda
grown focus drug compound facil overal
amerisourc segment hit qualiti concern
fda despit challeng expect
compani meet full-year fiscal revenu growth
rate guidanc midsingl digit longer term key growth
driver firm abil success negoti
smaller pharmaci band togeth forc
price discount expect compani strong
market posit help support success price
smaller pharmaci group well larger
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
outsid core distribut oper concern
born given struggl pharmedium
segment nevertheless pleas manag
chosen refocu firm back toward optim
pharmaceut distribut oper institut
billion share repurchas program along increas
dividend believ capit alloc strategi
better sharehold
amerisourc report mix quarter oper
amerisourc report mix quarter main
take-away continu stabil core drug
distribut oper fact specialti distribut
oper seem hit cylind amerisourc
largest specialti distributor believ
solid result segment major posit price
volatil core pharmaceut distribut busi
remain stabl posit sign addit
manag mention abl smoothli finish
integr believ recent infrastructur
invest begun payoff contribut
greater distribut effici find develop
encourag reiter fair valu
estim wide moat rate amerisourc also recent
distributor earlier year integr process
asset correspond client book ad
materi result believ solid oper
move add firm top-tier distribut
asset grow client book enhanc wide econom
case last quarter materi
headwind amerisourc non-drug wholes
busi particular continu major
headwind relat firm drug compound
manufactur key
facil close given
manufactur concern rais recent fda
inspect cost bring facil par
major drag result firm uncertain
abl bring asset back on-line accordingli
manag gave conserv outlook
guidanc leeri acquisit fall
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
